secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125927
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing
--------------------------------------------------------------------------------

- Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
- Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.
- Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.
- Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.
- Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/0000950170-24-125927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017024125927/fulc-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer